&nbsp;

OntarioCervicalScreeningProgramFactSheet-other-languages.zip

New

Nov 2025

Regimen

OXALRALT+ZOLB

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

New Drug Funding Program

Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2025

Drug

amivantamab

Other Name(s): Rybrevant®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Dec 2025

Regimen

ALEC

Cancer Type:

Lung,

Non-Small Cell

Intent: Adjuvant

Funding:

Exceptional Access Program

alectinib - Adjuvant treatment of ALK-positive non-small cell lung cancer, according to specific criteria

Drugs Used:

alectinib

... Show more tags

Quick Link(s):

Regimen Monograph

Nov 2025

Document

OH-Indigenous-cancer-strategy_EN.pdf

New

Dec 2025

Document

OH-Indigenous-cancer-strategy_FR.pdf

New

Dec 2025

Document

OH-Indigenous-cancer-strategy-executive-summary_EN.pdf

New

Dec 2025

Document

OH-Indigenous-cancer-strategy-executive-summary_FR.pdf

New

Dec 2025

Regimen

ANASRIBO

Cancer Type:

Breast

Intent: Adjuvant

Funding:

ODB - General Benefit

anastrozole

Drugs Used:

anastrozole,

ribociclib (Unfunded)

... Show more tags

Quick Link(s):

Regimen Monograph

Dec 2025

Regimen

OXALRALT+BEVA

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Funding:

New Drug Funding Program

Bevacizumab (Biosimilar) - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

New Drug Funding Program

Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Dec 2025

Document